Edward H Ha

Title: Edward H Ha: Innovator in Antibody-Oligonucleotide Conjugates

Introduction

Edward H Ha is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody-oligonucleotide conjugates. With a total of 2 patents, his work is paving the way for advancements in targeted therapies.

Latest Patents

Edward H Ha's latest patents include innovative conjugates that comprise a targeting protein, such as an anti-TM4SF1 antibody or its binding fragments. These conjugates are designed for specific applications in therapeutic settings. Additionally, he has developed antibody-drug conjugates (ADCs) that incorporate anti-TM4SF1 antibodies, along with methods for their use. These advancements highlight his commitment to enhancing treatment options through targeted drug delivery.

Career Highlights

Edward H Ha is currently associated with Angiex, Inc., where he continues to push the boundaries of research and development in his field. His work is characterized by a focus on creating effective therapeutic solutions that leverage the power of antibodies.

Collaborations

Some of his notable coworkers include Paul A Jaminet and Shou-Ching S Jaminet, who contribute to the collaborative environment that fosters innovation at Angiex, Inc.

Conclusion

Edward H Ha's contributions to the field of biotechnology, particularly through his patents on antibody-oligonucleotide conjugates, demonstrate his role as a key innovator. His work continues to influence the development of targeted therapies, showcasing the importance of innovation in healthcare.